Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suzanne Hayman

Showing results (41-50 of 72) with videos related to

Pageof 8
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2024
Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel TherapiesCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Morie Gertz, Betsy Laplant, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2026
Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple MyelomaShaji Kumar, Betsy Knopf, Erik Asmus, et al.
British Journal of Haematology|May 10, 2026
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotypeMatthew J Rees, Binoy Yohannan, Susan Geyer, et al.
Blood|June 9, 2025
Eliminating the need for sequential confirmation of response in multiple myelomaJean-Sébastien Claveau, Prashant Kapoor, Moritz Binder, et al.
Leukemia|June 17, 2024
Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessmentJean-Sébastien Claveau, David L Murray, Angela Dispenzieri, et al.
American Journal of Hematology|January 3, 2022
Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcomeMarcella Kaddoura, Moritz Binder, David Dingli, et al.
American Journal of Hematology|July 18, 2018
Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal proteinMarcella Tschautscher, Vincent Rajkumar, Angela Dispenzieri, et al.
Leukemia|December 9, 2022
Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessmentJean-Sébastien Claveau, David L Murray, Angela Dispenzieri, et al.
American Journal of Hematology|December 16, 2020
Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myelomaJoselle Cook, Isla Johnson, Alexandra Higgins, et al.
Pageof 8

Showing results (41-50 of 72) with videos related to

Sort By:
Pageof 8
Clinical Lymphoma, Myeloma & Leukemia|July 2, 2024
Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel TherapiesCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemiaIrene M Ghobrial, Morie Gertz, Betsy Laplant, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 18, 2026
Ixazomib, Cyclophosphamide, and Dexamethasone (ICd), With or Without Daratumumab in Relapsed Multiple MyelomaShaji Kumar, Betsy Knopf, Erik Asmus, et al.
British Journal of Haematology|May 10, 2026
Predictors of renal response in AL amyloidosis following anti-plasma cell therapy: The impact of baseline serum free light chain levels and light chain isotypeMatthew J Rees, Binoy Yohannan, Susan Geyer, et al.
Blood|June 9, 2025
Eliminating the need for sequential confirmation of response in multiple myelomaJean-Sébastien Claveau, Prashant Kapoor, Moritz Binder, et al.
Leukemia|June 17, 2024
Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessmentJean-Sébastien Claveau, David L Murray, Angela Dispenzieri, et al.
American Journal of Hematology|January 3, 2022
Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcomeMarcella Kaddoura, Moritz Binder, David Dingli, et al.
American Journal of Hematology|July 18, 2018
Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal proteinMarcella Tschautscher, Vincent Rajkumar, Angela Dispenzieri, et al.
Leukemia|December 9, 2022
Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessmentJean-Sébastien Claveau, David L Murray, Angela Dispenzieri, et al.
American Journal of Hematology|December 16, 2020
Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myelomaJoselle Cook, Isla Johnson, Alexandra Higgins, et al.
Pageof 8